Business Wire

ESI-GROUP/ENSAM

Share
ESI Group, in Collaboration With ENSAM, Deploys in Open Source Its "Inspector" Software

Regulatory News:

ESI Group (ISIN Code: FR0004110310, Mnemo: ESI), a global simulation and virtual prototyping software partner for industry, announces the open-source release of its Inspector software; an opening for the scientific community, industrial collaboration, and innovation.

Inspector is a visual and interactive data exploration software that can analyze a large volume of data to extract useful information that can be applied in the following contexts: predictive maintenance, cybersecurity, control, and analysis of machine learning algorithms.

By making Inspector software available to as many people as possible, ESI Group continues its commitment to the industrial and academic ecosystems, offering them the possibility of working on a reliable and customizable solution to meet the technical challenges and specific needs of the community.

ENSAM (Ecole Nationale Supérieure d'Arts et Métiers) will lead the development and expansion of Inspector, as part of the continuum of sponsorship and co-creation activities already in progress between ESI Group and ENSAM. This collaboration has been reinforced with their mutual involvement in the DesCartes program led by the CNRS in Singapore, the CREATE-ID international research chair, and through the ESI - ENSAM virtual engineering laboratory .

This open-source approach has many advantages. First, it allows the community to use the software in an optimal and fast way, thus, enabling the scientific community to benefit from new functionalities adapted to the requirements of each user, as well as from security improvements. Secondly, through its approach, ESI Group wishes to offer an opportunity to benefit from a software whose reliability has been proven over the years by its customers in various industries, including Automotive and Aeronautics. “Inspector” will continue to evolve and adapt to the needs of the community thanks to the collaboration of the numerous stakeholders.

Several industry players and “Inspector” users have expressed interest and support for ESI Group's initiative to deploy its data analysis software in open source. This is the case, for example, with CNS.

Stephane Perrin, Managing Director of CNS states: "The decision taken by ESI Group is a great illustration of the Group’s dedication to the innovation and scientific ecosystem with its cutting-edge technologies. At CNS, a Network and Security expertise company, we are mobilized to ensure the future of Inspector. In addition to integrating Inspector into our continuous network auditing software suite, we will also soon offer support for the software via our business unit dedicated to innovative solutions."

Emmanuel Leroy, EVP Product, Innovation & Industry Solutions at ESI Group said: "Data and open source are the two main keywords of this new coordinated action with ENSAM. We are delighted to be able to take our collaboration a step further while contributing to academic and industrial research and innovation. "Inspector" will provide users with a tool for analyzing large volumes of data to optimize the performance of manufacturing processes. In a period where data is becoming key but remains expensive; I am convinced that this open-source release will open opportunities for industrial players, whether they are large companies or startups."

Information on how to obtain the Inspector download and installation links

The "Inspector" module can be retrieved as an archive (674MB) with the following command: sftp inspector@jibleo.com :source_code/inendi-inspector_opensource_export_2022-01-27.tgz.

The password associated with the SFTP account "inspector" is "ut!iep2E" and the checksum sha256 of the archive is d0404dd13c80ec8a4e32f406986731025881097ed03fa47a4af77827744f1000

The location of the Gitlab project from which the export was made is the following: https://gitlab.com/inendi/inspector

The software can now be installed with the following command (as indicated in the documentation on the Gitlab project homepage): flatpak install --user -y https://inendi.gitlab.io/inspector/install.flatpakref

About ESI Group
Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation. Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high-level specialists around the world and reported 2021 sales of €136.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information, go to www.esi-group.com .

Follow ESI:  LinkedInFacebookTwitterYouTube

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye